Video

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

Author(s):

Shaji Kumar, MD

Shaji Kumar, MD, reviews the results of the phase 3 study evaluating the use of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Related Videos
Sagar Lonial, MD, FACP
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Bertrand Arnulf, MD, PhD
Philip McCarthy, MD, director emeritus, Transplant & Cellular Therapy Program, member, Tumor Immunology and Immunotherapy Program, Roswell Park Comprehensive Cancer Center
Amrita Krishnan, MD
Rahul Banerjee, MD, FACP
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Pieter Sonneveld, MD, PhD
Related Content
Meletios A. Dimopoulos, MD, professor, chairman, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine
September 6th 2024

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Rahul Banerjee MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
September 2nd 2024

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Courtney Van Houzen, PharmD
August 29th 2024

Stepwise Approach Helps Ease the Integration of BiTEs Into Community Cancer Centers

Rahul Banerjee MD, FACP, physician-researcher, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
August 27th 2024

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma